SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Rybakowski JK. Int. J. Psychiatry Clin. Prac. 2020; 24(4): 330-340.

Copyright

(Copyright © 2020, Informa - Taylor and Francis Group)

DOI

10.1080/13651501.2020.1775855

PMID

33169645

Abstract

OBJECTIVES: A narrative review of past, present, and future of lithium use in psychiatry.
METHODS: The most important references on the topic were reviewed with special emphasis on the author's works.
RESULTS: The history of medical and psychiatric use of lithium dates back to more than one and a half-century ago. However, modern psychiatric history began with the publication of John Cade, in 1949, showing a therapeutic effect of lithium in mania. Currently, lithium is a drug of choice as a mood-stabilizer for the maintenance treatment of the bipolar disorder. The second most important use of lithium is probably augmentation of antidepressants in treatment-resistant depression. In addition to its mood-stabilizing properties, lithium exerts anti-suicidal, immunomodulatory, and neuroprotective action. The drug may protect against dementia and some promising effects of lithium in neurodegenerative disorders have been observed.
CONCLUSION: Given the clinical and biological properties of lithium, this drug is presently greatly underutilized in mood disorders. Therefore, the efforts should be undertaken for challenging a skepticism about the use of lithium and optimizing its long-term administration. In such a way, more patients with mood disorders can become the beneficiaries of lithium's therapeutic action. KEY POINTS Lithium is a drug of choice as a mood-stabiliser for the maintenance treatment of bipolar disorder. Augmentation of antidepressants by lithium is one of the best strategies in treatment-resistant depression. Lithium exerts anti-suicidal, immunomodulatory, and neuroprotective action and may protect against dementia. Despite the evidence for the efficacy and added favourable properties, lithium is greatly underutilised in mood disorders. Challenging a scepticism about the use of lithium and optimising its long-term administration can make more patients with mood disorders the beneficiaries of lithium's therapeutic action.


Language: en

Keywords

Antimanic Agents; bipolar disorder; Bipolar Disorder; Dementia; Depressive Disorder, Treatment-Resistant; herpes; Humans; Lithium; Lithium Compounds; mood-stabiliser; neuroprotection; Neuroprotective Agents; suicide; Suicide Prevention

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print